NASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis $33.07 +0.08 (+0.24%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$32.71▼$34.1050-Day Range$28.97▼$38.2052-Week Range$25.77▼$50.23Volume578,550 shsAverage Volume655,210 shsMarket Capitalization$2.20 billionP/E RatioN/ADividend YieldN/APrice Target$64.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get CG Oncology alerts: Email Address CG Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside93.5% Upside$64.00 Price TargetShort InterestBearish14.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.64) to ($1.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.04 out of 5 starsMedical Sector825th out of 936 stocksBiological Products, Except Diagnostic Industry142nd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCG Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCG Oncology has only been the subject of 4 research reports in the past 90 days.Read more about CG Oncology's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.37% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 8.8.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGON. Previous Next 3.2 News and Social Media Coverage News SentimentCG Oncology has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CG Oncology this week, compared to 3 articles on an average week.Search Interest1 people have searched for CGON on MarketBeat in the last 30 days. MarketBeat FollowsOnly 4 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CG Oncology are expected to decrease in the coming year, from ($1.64) to ($1.97) per share.Read more about CG Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About CG Oncology Stock (NASDAQ:CGON)CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Read More CGON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGON Stock News HeadlinesJuly 25 at 8:14 AM | finance.yahoo.comInstitutional investors in CG Oncology, Inc. (NASDAQ:CGON) must be dismayed after prices dropped by 13% last weekJuly 16, 2024 | americanbankingnews.comCG Oncology, Inc.'s Lock-Up Period Will Expire on July 23rd (NASDAQ:CGON)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 9, 2024 | seekingalpha.comCG Oncology Bringing Undervalued Innovation To Bladder CancerJune 6, 2024 | globenewswire.comCG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBCMay 24, 2024 | msn.comCG Oncology climbs 10% on Phase 2 data for bladder cancer drugMay 24, 2024 | globenewswire.comCG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual MeetingMay 14, 2024 | markets.businessinsider.comDecoding 10 Analyst Evaluations For CG OncologyJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 14, 2024 | msn.comGoldman Sachs Upgrades CG Oncology (CGON)May 10, 2024 | markets.businessinsider.comBuy Rating for CG Oncology on Strong Trial Results and Market PotentialMay 9, 2024 | globenewswire.comCG Oncology Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 6, 2024 | markets.businessinsider.comCG Oncology’s Cretostimogene Shows Promising Efficacy and Safety in NMIBC Treatment, Merits Buy RatingMay 6, 2024 | seekingalpha.comCG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further ValueMay 4, 2024 | markets.businessinsider.comBuy Rating Justified by CG Oncology’s Cretosmogene Efficacy and Market PositioningMay 3, 2024 | seekingalpha.comCG Oncology reports data from Phase 3 bladder cancer studyMay 3, 2024 | seekingalpha.comCG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage TrialsMay 3, 2024 | globenewswire.comCretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder CancerSee More Headlines Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CUSIPN/A CIK1991792 Webcgoncology.com Phone949-419-6203FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$64.00 High Stock Price Target$75.00 Low Stock Price Target$50.00 Potential Upside/Downside+92.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio57.95 Quick Ratio57.95 Sales & Book Value Annual Sales$200,000.00 Price / Sales11,065.57 Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book-17.12Miscellaneous Outstanding Shares66,640,000Free FloatN/AMarket Cap$2.21 billion OptionableOptionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Arthur Kuan (Age 33)Chairman & CEO Comp: $640.97kMr. Ambaw Bellete M.S. (Age 53)President & COO Comp: $1.06MDr. Vijay Kasturi M.D. (Age 56)Chief Medical Officer Comp: $212.24kMs. Corleen M. Roche (Age 57)CFO & Secretary Ms. Amy SteeleVice President of Finance, Accounting & AdministrationMr. Swapnil Bhargava Ph.D.Chief Technical OfficerMr. Bing KungVice President of Corporate DevelopmentMore ExecutivesKey CompetitorsRevolution MedicinesNASDAQ:RVMDRepligenNASDAQ:RGENHalozyme TherapeuticsNASDAQ:HALOExelixisNASDAQ:EXELKrystal BiotechNASDAQ:KRYSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 24,801 shares on 7/26/2024Ownership: 0.134%RA Capital Management L.P.Bought 1,397,433 shares on 5/17/2024Ownership: 2.097%Janus Henderson Group PLCBought 1,521,432 shares on 5/16/2024Ownership: 2.283%Blackstone Inc.Bought 25,000 shares on 5/16/2024Ownership: 0.038%California State Teachers Retirement SystemBought 2,341 shares on 5/16/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions CGON Stock Analysis - Frequently Asked Questions How have CGON shares performed this year? CG Oncology's stock was trading at $37.17 at the start of the year. Since then, CGON shares have decreased by 11.0% and is now trading at $33.07. View the best growth stocks for 2024 here. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) released its earnings results on Thursday, May, 9th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.01. The business had revenue of $0.53 million for the quarter. When did CG Oncology IPO? CG Oncology (CGON) raised $380 million in an initial public offering (IPO) on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share. When did CG Oncology's lock-up period expire? CG Oncology's lock-up period expired on Tuesday, July 23rd. CG Oncology had issued 20,000,000 shares in its IPO on January 25th. The total size of the offering was $380,000,000 based on an initial share price of $19.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period. Who are CG Oncology's major shareholders? CG Oncology's top institutional investors include Bank of New York Mellon Corp (0.13%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche and Vijay Kasturi. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGON) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
